Macrophages – The Key Actors in Adipose Tissue Remodeling and Dysfunction by Stojanović, Sanja & Najman, Stevo
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Macrophages – The Key Actors in Adipose Tissue
Remodeling and Dysfunction
Sanja Stojanović and Stevo Najman
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62152
Abstract
Adipose tissue (AT) is a very important endocrine and paracrine organ that regulates oth‐
er tissues and organs. Dysfunction of AT leads to a wide range of disorders like obesity,
insulin resistance, diabetes mellitus, cardiac disorders, tumors and others. Adipose tissue
macrophages (ATMs) are the key actors in AT remodeling and dysfunction. Their role in
AT dysfunction is nowadays increasingly investigated, but still their interplay and molec‐
ular mechanisms of actions have not been fully elucidated. In this chapter, we summar‐
ized the current knowledge about the role of macrophages in AT remodeling,
dysfunction and related disorders and indicate the potential directions for future re‐
search.
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1. Introduction
Adipose tissue (AT) was previously considered to be only a fat depot. Today, it is well known
that AT secretes a large number of proteins collectively termed as adipokines (adiponectin,
leptin, resistin and inflammatory cytokines TNF-α, IL6, IL8, IL1, IL10, IL18 and TGF-β) that
are responsible for many different processes in the body. Therefore, AT is considered to be a
highly active metabolic, endocrine and paracrine organ that regulates other tissues and organs.
AT is very heterogeneous and consists of different cell types such as: adipocytes, pre-adipo‐
cytes, endothelial cells, fibroblasts, mesenchymal stem cells and immune cells (mast cells,
lymphocytes and macrophages). Adipose tissue macrophages (ATMs) are cells that are
responsible for AT remodeling. There are two types of ATMs, M1 (classically activated) or
inflammatory macrophages and M2 (alternatively activated), anti-inflammatory or reparatory
macrophages. The role of ATMs in disorders such as obesity, insulin resistance, diabetes
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mellitus, cardiac disorders, tumors and others is nowadays increasingly investigated, but still
their interplay and molecular mechanisms of actions have not been fully elucidated. This
chapter provides an overview of current knowledge about the role of macrophages in AT
remodeling, dysfunction and related disorders and indicates the potential directions for future
research.
2. Adipose Tissue Macrophages (ATMs)
Although adipocytes play a central role in adipose tissue (AT) remodeling, an increasing
attention is directed toward adipose tissue macrophages (ATMs). Since adipose tissue
remodeling is nowadays considered as chronic inflammation, ATMs and their interaction with
adipocytes are key events that orchestrate the adipose tissue remodeling process.
Resident ATMs are very heterogenic population of cells that is reflected on their function in
AT [1, 2]. During AT remodeling, factors that are released from AT induce the recruitment of
monocytes into AT. It has been shown that most of the macrophages in AT are derived from
bone marrow [3, 4].
There are two types of ATMs: M1 (classically activated) and M2 (alternatively activated)
macrophages. They are characterized based on their polarization state, the expression of
particular antigens [2, 5, 6] and secretion products. M1 (classically activated) macrophages,
also called pro-inflammatory macrophages, are dominant type of macrophages during AT
expansion and inflammation. They are characteristic of obese AT. Classically activated
macrophages can be induced by LPS and the Th1 cytokine IFN-γ and express high levels of
pro-inflammatory mediators including F4/80, CD11c, TNF-α, IL-6, iNOS, CCR2, IL-12 and
IL-23 [6–9]. M2 (alternatively activated) macrophages, also called reparatory or anti-inflam‐
matory macrophages, are dominant in lean AT. M2 macrophages are responsible for AT
homeostasis, tissue repair and immunosuppression. Exposure of macrophages to the TH2
cytokine IL-4 produces M2 phenotype. They express F4/80, CD301, arginase 1 [6, 7] and CD163
and high levels of scavenger, mannose, and galactose-type receptors. They secrete anti-
inflammatory cytokines such as IL-10 and IL-1 receptor antagonist [8, 9] and are shown to
inhibit NOS (iNOS) activity. M2 macrophages preserve normal adipocyte function by pro‐
moting tissue repair and angiogenesis in an increasing AT mass [2, 10].
3. The role of ATMs in adipose tissue dysfunction and related disorders
The exact role of ATMs in AT dysfunction and related disorders is still not known. In recent
years, a lot of research has been done, and it has been shown that the balance between M1 and
M2 macrophages is crucial for maintaining normal adipocyte function and AT homeostasis.
Obesity is a very common chronic disease that leads to the development of insulin resistance,
diabetes mellitus, cardiac disorders and others [3, 4, 11–15]. Obesity is characterized as a low-
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grade chronic inflammation with unbalanced production of pro- and anti-inflammatory
adipokines that contributes to the development of metabolic syndrome [4, 11–14, 16] and may
be involved in a variety of physiologic and pathologic processes [17]. In obesity, the balance
between M1 and M2 macrophages is disturbed and moved toward M1 inflammatory macro‐
phages. There are two mechanisms of imbalance occurrence: infiltration of monocytes from
circulation under the influence of molecules secreted from growing AT and “phenotypic
switching” between M1 and M2 macrophages. During the AT growth, adipocytes secrete
products that promote the production of macrophage inflammatory cytokines [18, 19]. These
products influence the polarization of resident macrophages. A model of “phenotypic
switching” of macrophages has been reported by Lumeng et al. in 2007 [6]. Their model
emphasized that obesity is accompanied by a transformation in the polarized states of
macrophages, from an “alternatively activated” M2 that primarily accumulates during
negative energy balance to a more pro-inflammatory “classically activated” M1 macrophages.
This phenotypic change from M2 to M1 polarization in obese adipose tissue leads to adipose
tissue inflammation [20–23]. Macrophages that are infiltrated into AT from circulation are an
important source of inflammation in obese AT. Chemokines are small pro-inflammatory
molecules that promote macrophage mobilization from bone marrow into tissues. Increased
expression of chemokines in obese adipose tissue has been implicated in the control of
monocyte recruitment to the adipose tissue. During the expansion of AT, secretion of pro-
inflammatory cytokines is upregulated and they are released into the circulation. It is shown
that MCP-1/CCR2 pathways have pathophysiological role in macrophage infiltration into
obese adipose tissue [24, 25]. MCP-1 plays a role in the recruitment of macrophages into obese
adipose tissue. Increased levels of MCP-1, CXCL14, MIP-1α, MCP-2, MCP-3 and RANTES can
be observed in AT of mice with genetic or DIO [15, 26]. CCR2 expressed in bone marrow cells
is involved in macrophage infiltration into obese adipose tissue [27]. In addition to the MCP-1/
CCR2 pathway, there are several reports suggesting the potential involvement of other
chemotactic factors in obesity-induced macrophage infiltration such as osteopontin, angio‐
poietin-like protein 2 and CXCL14 [26, 28, 29]. Downregulation of MKP-1 is critical for
increased production of MCP-1 during adipocyte hypertrophy [30]. Increased number of pro-
inflammatory CD11c+ M1-like ATMs in established obesity is a result of increased monocyte
migration into AT, polarization of ATMs toward the M1 and a low level of proliferation of
these cells after they become ATMs [31]. Adipocyte hyperplasia and hypertrophy both
contribute to the expansion of AT that leads to hypoxia, adipocyte cell death, enhanced
chemokine secretion and dysregulation in fatty acid fluxes [32]. Necrosis of adipocytes is a
prominent phagocytic stimulus that regulates ATMs infiltration. Macrophages aggregate
around these dead adipocytes forming crown-like structures (CLSs) in advanced obesity [33–
36]. Macrophages fuse to form multinucleated giant cells and to phagocyte the residual lipid
droplet. They become increasingly activated in their attempt to clear the potentially cytotoxic
remnant lipid droplet forming large lipid-laden multinucleated syncytia in the process, a
commonly accepted hallmark of chronic inflammation [7, 33]. Macrophages aggregate to
constitute a CLS surrounding dead adipocytes in advanced obesity [6, 34, 35]. Electron
microscopic analysis also revealed lipid-laden phagolysosomes in macrophages within CLS
[33]. It is shown that massive adipocyte death can indeed drive rapid accumulation of ATMs
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as an integral element in the remodeling of fat pads [37] by using a transgenic model of
inducible lipoatrophy. The number of necrotic adipocytes positively correlates with average
adipocyte size in obese mice and other mouse models of adipocyte hypertrophy [33, 36, 38]. It
has been suggested that macrophage localization and infiltration are strongly linked to adipose
cell death [9, 33]. It is shown that adipocyte death and/or the death receptor Fas signaling
contribute to obesity-induced adipose tissue inflammation and systemic insulin resistance [39,
40]. TNF-alpha induces pro-apoptotic and/or death signals in a variety of cell types, it is
therefore interesting to speculate that hypertrophied adipocytes, which are stimulated and
thus dying by macrophage-derived TNF-alpha, can release saturated fatty acids as an endog‐
enous danger signal that reports their diseased state to macrophages in obese adipose tissue
[4]. CCL5 production by fibroblasts, platelets and monocytes/macrophages is a particular
feature of inflammatory disorders such as atherosclerosis [41, 42]. It is shown that CCL5,
through CCR1 and CCR5, contributes to transendothelial migration of monocytes and T cells
in atherogenic lesions [43]. CCL5 provides anti-apoptotic signals via the Akt and Erk1/2
pathways, which could then favor the scavenging role of tissue macrophages [44]. Obese
adipose tissue is shown to be poorly oxygenated [45, 46]. During the expansion of AT, hypoxic
areas are created due to adipocyte hypertrophy [47] that leads to the upregulated secretion of
macrophage migration inhibitory factor (MIF), the matrix metalloproteinases MMP-2 and
MMP-9, IL-6, Angplt4, PAI-1, VEGF and leptin [46, 48–50] that all together lead to inflamma‐
tion. Leptin and VEGF are hypoxia-associated genes that are directly regulated by HIF-1, a
master regulator of hypoxia and oxygen homeostasis is HIF-1 [51, 52]. Sun et al., 2011, suggest
that hypoxia-induced fibrosis that follows AT inflammation may be a key factor that ultimately
stimulates the local inflammatory responses [2]. Free fatty acids are stored in AT in the form
of triglycerides and can cause lipotoxic side effects when are present in high amounts in tissues.
During adipocytes’ hypertrophy FFAs are released through lipolysis and cause inflammatory
response. By increasing local extracellular lipid concentrations, FFAs lead to the accumulation
of ATMs [53, 54]. FFAs may act as ligands for the TLR4 complex, like LPS [55]. Activation of
TLR4 complex by saturated fatty acids may be involved in the regulation of metabolic
homeostasis within the adipose tissue. FFAs contribute to the polarization of infiltrated
macrophages toward M1 [4]. It is shown that M1 population of macrophages is dominant in
the states of overnutrition and that inflammatory response is mediated by FFAs [7, 56].
4. The role of macrophages in tumors
The exact role of macrophages in tumor development and progression is still not fully
examined, but it is shown that macrophages are associated with solid tumors. Studies
performed with various tumors showed that tumor-associated macrophages (TAMs) have a
lot of similarities with M2 type of macrophages with high expression of IL-10 and low
expression of IL-12. The expression of CD163 is high in TAMs and is used as a reliable marker
for TAMs [57, 58]. These are potential indicators that TAMs are M2 polarized macrophages
[59] with potent immunosuppressive functions. It is shown that TAMs possess anti-inflam‐
matory, pro-angiogenic and tumor-promoting properties [60] and are characteristic of the late
stage of tumor progression. Adipose tissue may support breast and prostate cancer develop‐
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ment and progression via secretion of pro-inflammatory cytokines. Studies performed with
mammary gland-associated AT and periprostatic AT showed that secretion of pro-inflamma‐
tory cytokines is increased in surrounded AT [61].
5. Conclusions and future perspectives
Further investigations are needed to understand the molecular mechanisms by which ATMs
participate in the development of various disorders, which would open the door to the findings
and development of new molecular target therapies. Dalmas et al., 2015 [62], suggested that
inhibition of interferon regulatory factor 5 (IRF5), transcription factor implicated in polariza‐
tion of macrophages towards M1, could be a potential strategy to control pathological AT
expansion in obesity and insulin resistance. Repolarization of ATMs could also be one of the
possible ways of treatment, but further investigation in this direction is needed.
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